Heron Therapeutics Inc
HRTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.79M
Close$
$3.67
1143.5% upside
Current Fair Value
1143.5% upsideUndervalued by 1143.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $53.79 Million |
|---|---|
| Enterprise Value | $181.42 Million |
| Earnings per Share | $-0.12 |
| Beta | 1.63 |
| Outstanding Shares | 190,335,000 |
Return
| Return on Equity | -492.89% |
|---|---|
| Return on Assets | -13.50% |
| Return on Invested Capital | -10.18% |
Valuation & Multiples
| P/E Ratio | -1.48 |
|---|---|
| PEG | -1.14 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.2 |
| Enterprise Value to EBIT | -11.13 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.82 |
| Debt to Equity | 21.48 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$42.19 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.03
Consensus analyst estimateRevenue Estimate
$37.50 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 187.26% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 71.02% |
|---|---|
| Total Invested | $20,210▼ 99.97% |
| Investors Holding | 6▼ 164.00% |
About Heron Therapeutics Inc
128 employees
CEO: Barry Quart
Heron Therapeutics, Inc. is a biotechnology firm dedicated to developing innovative therapeutic solutions for significant unmet patient needs. At the heart of its pipeline is the proprietary Biochronomer drug delivery system. This techno...